Lataa...
Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection
Atazanavir (ATV) is a new azapeptide protease inhibitor recently approved and currently used at a fixed dose of either 300 mg once per day (q.d.) in combination with 100 mg ritonavir (RTV) or 400 mg q.d. without boosting. ATV is highly bound to plasma proteins and extensively metabolized by CYP3A4....
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology
2006
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1635184/ https://ncbi.nlm.nih.gov/pubmed/16940065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00098-06 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|